Kamada Ltd.
KMDA
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunizatioā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.66
Price+0.61%
$0.04
1Y
Price
Market Cap
$382.984m
Small
Price/Earnings 3y Avg5y Avg
20.8x
Premium
Premium
Financials Overview
Key metrics over the past few years+21.7%
EBITDA Margin+16.5%
Net Profit Margin+13.4%
Free Cash Flow MarginRevenue
$169.517m
+5.3%
1y CAGR+9.5%
3y CAGR+13.3%
5y CAGREarnings
$19.011m
+31.5%
1y CAGR+187.7%
3y CAGR+139.7%
5y CAGREPS
$0.34
+36.0%
1y CAGR+167.6%
3y CAGR+125.7%
5y CAGRBook Value
$259.954m
$368.173m
Assets$108.219m
Liabilities$11.415m
DebtDebt to Assets
3.1%
0.3x
Debt to EBITDAFree Cash Flow
$31.589m
-14.3%
1y CAGR+793.5%
3y CAGR+669.5%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company